Fate therapeutics presents patient case study demonstrating clinical activity of ft596 in refractory diffuse large b-cell lymphoma

Off-the-shelf, ipsc-derived car nk cell product candidate drives partial response at first dose level of 30 million cells

FATE Ratings Summary

FATE Quant Ranking